COMPASS Pathways (CMPS) is trading down at $11.60 (-2.52%), as of the latest quote. It operates in the Health Care sector.
COMPASS Pathways net income history (FY2019–FY2025)
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$21.2M | −$51.4M | −$83.2M | −$110.4M | −$136.9M | −$178.2M | −$179.0M |
| Net income | −$19.6M | −$60.3M | −$71.7M | −$91.5M | −$118.5M | −$155.1M | −$287.9M |
| EPS (diluted) | −$2.62 | −$3.55 | −$1.79 | −$2.16 | −$2.32 | −$2.30 | −$3.08 |
| Balance sheet | |||||||
| Cash and equivalents | $25.0M | $190.3M | $273.2M | $143.2M | $220.2M | $165.1M | $149.6M |
| Total assets | $32.4M | $203.5M | $300.9M | $197.3M | $276.0M | $213.7M | $210.3M |
| Total liabilities | $23.9M | $6.89M | $16.5M | $16.0M | $50.2M | $59.0M | $263.2M |
| Long-term debt | — | — | — | $0 | $28.8M | $24.7M | $14.1M |
| Shareholders' equity | −$30.4M | $196.6M | $284.4M | $181.3M | $225.7M | $154.7M | −$52.8M |
| Cash flow | |||||||
| Operating cash flow | −$17.8M | −$41.4M | −$67.7M | −$105.5M | −$97.4M | −$119.2M | −$157.2M |
| Capital expenditure | $165.0K | $131.0K | $334.0K | $596.0K | $66.0K | $0 | — |
| Free cash flow | −$18.0M | −$41.5M | −$68.1M | −$106.0M | −$97.4M | −$119.2M | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$47.9M | −$48.4M | −$49.6M | −$42.9M | −$40.5M | −$46.0M | −$42.9M | −$52.4M |
| Net income | −$38.5M | −$43.3M | −$17.9M | −$38.4M | −$137.7M | −$93.9M | $91.2M | −$253.8M |
| EPS (diluted) | −$0.56 | −$0.63 | −$0.24 | −$0.41 | −$1.44 | −$0.99 | −$0.30 | −$1.88 |
| Balance sheet | ||||||||
| Cash and equivalents | $207.0M | $165.1M | $260.1M | $221.9M | $185.9M | $149.6M | $466.0M | $433.3M |
| Total assets | $247.3M | $213.7M | $319.1M | $293.5M | $255.6M | $210.3M | $531.7M | $504.6M |
| Total liabilities | $54.3M | $59.0M | $123.7M | $131.0M | $218.0M | $263.2M | $205.1M | $420.0M |
| Long-term debt | $27.6M | $24.7M | $21.6M | $23.0M | $18.6M | $14.1M | $50.5M | $50.7M |
| Shareholders' equity | $193.0M | $154.7M | $195.5M | $162.6M | $37.6M | −$52.8M | $326.7M | $84.5M |
| Cash flow | ||||||||
| Operating cash flow | −$22.2M | −$41.8M | −$45.7M | −$38.7M | −$35.1M | −$37.8M | −$47.9M | −$40.3M |
| Capital expenditure | $0 | $0 | — | — | — | — | — | — |
| Free cash flow | −$22.2M | −$41.8M | — | — | — | — | — | — |
From COMPASS Pathways's 10-K, 10-Q, 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About COMPASS Pathways
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
Source: Wikipedia — Compass Pathways
- Headquarters
- Chesire, United Kingdom From SEC filings, Oct 2026
Recent News
No recent news mentioning COMPASS Pathways in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International